Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study

James Thrasher; Kristen Daniels; Sanjay Patel; Jacqueline Whetteckey; Hans-Juergen Woerle

doi:10.4158/ep13365.or

Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study

Endocrine Practice ◽

10.4158/ep13365.or ◽

2014 ◽

Vol 20 (5) ◽

pp. 412-420 ◽

Cited By ~ 15

Author(s):

James Thrasher ◽

Kristen Daniels ◽

Sanjay Patel ◽

Jacqueline Whetteckey ◽

Hans-Juergen Woerle

Keyword(s):

Type 2 Diabetes ◽

African American ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Black African ◽

Double Blind Placebo

Download Full-text

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

Diabetes Care ◽

10.2337/dc12-0706 ◽

2012 ◽

Vol 36 (2) ◽

pp. 237-244 ◽

Cited By ~ 120

Author(s):

J. B. McGill ◽

L. Sloan ◽

J. Newman ◽

S. Patel ◽

C. Sauce ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy

Download Full-text

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2011.01391.x ◽

2011 ◽

Vol 13 (7) ◽

pp. 653-661 ◽

Cited By ~ 117

Author(s):

R. Gomis ◽

R.-M. Espadero ◽

R. Jones ◽

H. J. Woerle ◽

K. A. Dugi

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Initial Combination Therapy ◽

Initial Combination

Download Full-text

Faculty Opinions recommendation of Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717961956.793465689 ◽

2012 ◽

Author(s):

Pierre Ronco ◽

Jean-Jacques Boffa

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion ◽

10.1185/03007990903156111 ◽

2009 ◽

Vol 25 (10) ◽

pp. 2361-2371 ◽

Cited By ~ 97

Author(s):

Richard E. Pratley ◽

Jane E.-B. Reusch ◽

Penny R. Fleck ◽

Craig A. Wilson ◽

Qais Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)

Diabetology International ◽

10.1007/s13340-014-0182-y ◽

2014 ◽

Vol 6 (2) ◽

pp. 104-116 ◽

Cited By ~ 30

Author(s):

Atsunori Kashiwagi ◽

Takanori Shiga ◽

Noriko Akiyama ◽

Kenichi Kazuta ◽

Atsushi Utsuno ◽

...

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

Diabetes Obesity and Metabolism ◽

10.1111/dom.12403 ◽

2015 ◽

Vol 17 (2) ◽

pp. 152-160 ◽

Cited By ~ 69

Author(s):

A. Kashiwagi ◽

H. Takahashi ◽

H. Ishikawa ◽

S. Yoshida ◽

K. Kazuta ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Renal Impairment ◽

Safety Evaluation ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension

Diabetes Obesity and Metabolism ◽

10.1111/dom.12235 ◽

2013 ◽

Vol 16 (5) ◽

pp. 418-425 ◽

Cited By ~ 32

Author(s):

T. Kadowaki ◽

K. Kondo

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study

Endocrinology Diabetes & Metabolism ◽

10.1002/edm2.222 ◽

2021 ◽

Author(s):

Linong Ji ◽

Ling Li ◽

Jianhua Ma ◽

Xuefeng Li ◽

Dongmei Li ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Chinese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

Diabetes Care ◽

10.2337/dc08-1035 ◽

2008 ◽

Vol 31 (12) ◽

pp. 2315-2317 ◽

Cited By ~ 159

Author(s):

R. A. DeFronzo ◽

P. R. Fleck ◽

C. A. Wilson ◽

Q. Mekki ◽

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Inadequate Glycemic Control

Download Full-text

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

International Journal of Clinical Practice ◽

10.1111/j.1742-1241.2008.01933.x ◽

2009 ◽

Vol 63 (1) ◽

pp. 46-55 ◽

Cited By ~ 149

Author(s):

M. A. Nauck ◽

G. C. Ellis ◽

P. R. Fleck ◽

C. A. Wilson ◽

Q. Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Metformin Therapy ◽

Dipeptidyl Peptidase 4 ◽

Metformin Monotherapy ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text